Allena Pharmaceuticals, Inc.
(NASDAQ : ALNA)

( )
ALNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-6.21%127.720.7%$1062.40m
MRKMerck & Co., Inc.
1.07%84.700.7%$636.75m
PFEPfizer Inc.
0.00%36.460.9%$629.75m
ABBVAbbVie, Inc.
1.77%76.472.3%$578.88m
BMYBristol-Myers Squibb Company
1.15%53.021.4%$522.05m
LLYEli Lilly and Company
0.16%108.631.0%$298.35m
NVSNovartis AG Sponsored ADR
-0.39%86.890.2%$144.58m
AZNAstraZeneca PLC Sponsored ADR
-0.59%43.871.2%$133.90m
GSKGlaxoSmithKline plc Sponsored ADR
0.12%42.520.2%$97.15m
SNYSanofi Sponsored ADR
-0.71%46.170.2%$75.70m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.29%52.530.1%$68.10m
LCILannett Company, Inc.
-1.84%11.7335.6%$15.44m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.87%1.691.6%$0.44m
EPIXESSA Pharma Inc
8.79%3.900.1%$0.11m

Company Profile

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.